- Home
- NAMS vs PTY Comparison
NAMS vs PTY Comparison
Compare NAMS & PTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- PTY
- Stock Information
- Founded
- NAMS 2019
- PTY 2002
- Country
- NAMS Netherlands
- PTY United States
- Employees
- NAMS N/A
- PTY N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- PTY Investment Managers
- Sector
- NAMS Health Care
- PTY Finance
- Exchange
- NAMS Nasdaq
- PTY Nasdaq
- Market Cap
- NAMS 3.1B
- PTY 2.8B
- IPO Year
- NAMS N/A
- PTY N/A
- Fundamental
- Price
- NAMS $40.29
- PTY $13.29
- Analyst Decision
- NAMS Strong Buy
- PTY
- Analyst Count
- NAMS 10
- PTY 0
- Target Price
- NAMS $44.80
- PTY N/A
- AVG Volume (30 Days)
- NAMS 1.0M
- PTY 550.4K
- Earning Date
- NAMS 11-05-2025
- PTY 01-01-0001
- Dividend Yield
- NAMS N/A
- PTY 9.65%
- EPS Growth
- NAMS N/A
- PTY N/A
- EPS
- NAMS N/A
- PTY N/A
- Revenue
- NAMS $35,243,000.00
- PTY N/A
- Revenue This Year
- NAMS N/A
- PTY N/A
- Revenue Next Year
- NAMS N/A
- PTY N/A
- P/E Ratio
- NAMS N/A
- PTY N/A
- Revenue Growth
- NAMS 4.91
- PTY N/A
- 52 Week Low
- NAMS $14.06
- PTY $11.92
- 52 Week High
- NAMS $41.47
- PTY $14.88
- Technical
- Relative Strength Index (RSI)
- NAMS 61.84
- PTY 41.91
- Support Level
- NAMS $36.59
- PTY $12.82
- Resistance Level
- NAMS $40.88
- PTY $13.75
- Average True Range (ATR)
- NAMS 2.59
- PTY 0.16
- MACD
- NAMS -0.09
- PTY -0.01
- Stochastic Oscillator
- NAMS 90.44
- PTY 48.44
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About PTY Pimco Corporate & Income Opportunity Fund
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.